Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 10.967
Filter
1.
Más Vita ; 3(2): 8-15, jun 2021. tab
Article in Spanish | LILACS, LIVECS | ID: biblio-1253888

ABSTRACT

La Homeopatía es una modalidad terapéutica que se practica desde el siglo XIX, siendo reconocida por la Organización Mundial de la Salud. En Cuba, con el desarrollo de la Medicina Natural y Tradicional (MNT), el uso de la Homeopatía se ha extendido y se ha incrementado el consumo de sus medicamentos. Objetivo: Caracterizar el consumo y el cumplimiento de las Buenas Prácticas de Preparación de medicamentos homeopáticos. Métodos: Se realizó un estudio descriptivo transversal del tipo consumo, en la Farmacia Homeopática Provincial de Santiago de Cuba. Resultados: El 94,03% del total de las ventas, fue mediante recetas médicas, entre los 12 medicamentos homeopáticos más prescriptos estuvieron la Drossera, Sambucus y Belladona. La especialidad con más prescripciones fue la de Pediatría con el 53,32%, recibiéndose recetas de 12 Instituciones de salud de la provincia. Dentro de los errores detectados en las recetas sin calidad predominó en el 87,35% la omisión de las potencias y errores en la nomenclatura del medicamento. En la valoración del cumplimiento de las normas de Buenas Prácticas de Preparación se obtuvo la puntuación de 83 puntos de 100, clasificándose el cumplimiento en dicho servicio con la categoría de Bien. La dispensación de los medicamentos homeopáticos resultó ser adecuada en el 100 % de los casos. Conclusión: Se comprobó el amplio uso de esta terapéutica en el territorio. Se detectaron deficiencias en la calidad de las recetas médicas. La dispensación constituyó un factor de impacto positivo en los pacientes(AU)


Homeopathy is a therapeutic modality that has been practiced since the 19th century, been recognized by the World Health Organization. In Cuba, with the development of Natural and Traditional Medicine (NTM), the use of Homeopathy has spread and the consumption of its medicines has increased. Objective: To characterize the consumption and compliance with the Good Practices for the Preparation of homeopathic medicines. Methods: A cross-sectional descriptive study of the consumption type was carried out in the Provincial Homeopathic Pharmacy of Santiago de Cuba. Results: 94.03% of total sales were through medical prescriptions, among the 12 most prescribed homeopathic medicines were Drossera, Sambucus and Belladonna. The specialty with the most prescriptions was Pediatrics with 53.32%, with prescriptions received from 12 health institutions in the province. Among the errors detected in the prescriptions without quality, 87.35% were due to omission of potencies and errors in the nomenclature of the drug. In the evaluation of compliance with the standards of Good Preparation Practices, a score of 83 points out of 100 was obtained, classifying compliance in this service with the category of Good. The dispensing of homeopathic medicines was adequate in 100 % of the cases. Conclusion: The wide use of this therapy in the territory was verified. Deficiencies were detected in the quality of medical prescriptions. Dispensing was a factor of positive impact on patients(AU)


Subject(s)
Humans , Male , Female , Homeopathic Pharmacy , Good Manipulation Practices , Pharmaceutical Trade , Therapeutics , Therapeutic Uses
2.
Med. U.P.B ; 40(1): 65-76, 03/03/2021. Ilus
Article in Spanish | LILACS, COLNAL | ID: biblio-1177500

ABSTRACT

Esta revisión abarca la historia, el origen, la síntesis biológica del cannabidiol (CBD), su interacción con el sistema de cannabinoides endógenos, las presentaciones para uso clínico, su farmacocinética, tolerabilidad y la evidencia actual de los usos en psiquiatría. Además del origen de su nombre y las precisiones de la taxonomía botánica de la cannabis, es de interés conocer a partir de estudios de polen fósil la cronología y ruta que siguió ancestralmente hasta la llegada a Europa y cómo allí se inició su estudio con la idea de introducirla en la farmacopea del momento y como modelo de estudio de trastornos cerebrales como las psicosis. Jacques Joseph Moreau de Tours (1804-1884), psiquiatra francés, la usó en forma de hachís y propició el consumo experimental por intelectuales de la época. Basado en la presunción de que intelectuales e individuos con una educación eran sujetos de estudio que podían proveer relatos más detallados y floridos de las experiencias vividas bajo sus efectos, Moreau de Tours concibió por primera vez que los efectos de la cannabis eran un paradigma experimental para el estudio de las psicosis. Luego experimentó su uso terapéutico con resultados negativos. En el caso del CBD, extraído de la cannabis, la psiquiatría contemporánea podría vislumbrar resultados más promisorios a través de la investigación clínica en diferentes indicaciones


This review covers the history, origin, and biological synthesis of Cannabidiol (CBD), together with its interaction with the endogenous cannabinoid system, its options for clinical use, its pharmacokinetics, its tolerability, and current evidence for indications in psychiatry. In addition to the origin of its name and the details of the botanical taxonomy of cannabis, it is a matter of interest to review fossil pollen studies to help us trace the chronology and route that it followed until it got to be known in Europe, and how was included in the pharmacological studies of the time, with the aim to use it as a model for studying brain disorders such as psychoses. French psychiatrist Jacques Joseph Moreau de Tours (1804-1884) used it in the form of hashish and encouraged its experimental consumption by intellectuals and famous artists of the time, who were then asked to provide detailed descriptions of their experiences under the effects of cannabis. Moreau de Tours was the first to conceive that the effects of cannabis were an experimental paradigm for the study of psychoses. He went on to experiment its therapeutic use with negative results. In the case of CBD, extracted from cannabis, contemporary psychiatry could foresee more promising results in its therapeutic effects through clinical research in different indications.


Esta revisão cobre a história, origem, síntese biológica do canabidiol (CBD), sua interação com o sistema canabinoide endógeno, apresentações para uso clínico, sua farmacocinética, tolerabilidade e evidências atuais de uso em psiquiatria. Além da origem do seu nome e dos detalhes da taxonomia botânica da cannabis, é interessante saber pelos estudos do pólen fóssil a cronologia e o percurso que ele percorreu ancestralmente até chegar à Europa e como começou seu estudo com a ideia lá para introduzi-lo na farmacopeia do momento e como um modelo para estudar distúrbios cerebrais como as psicoses. Jacques Joseph Moreau de Tours (1804-1884), psiquiatra francês, utilizou-o na forma de haxixe e estimulou o consumo experimental pelos intelectuais da época. Com base na suposição de que intelectuais e indivíduos educados eram sujeitos de estudo que poderiam fornecer relatos mais detalhados e floreados de experiências sob sua influência, Moreau de Tours primeiro concebeu que os efeitos da cannabis eram um paradigma experimental para o estudo das psicoses. Ele então experimentou seu uso terapêutico com resultados negativos. No caso do CBD, extraído da cannabis, a psiquiatria contemporânea poderia ver resultados mais promissores por meio de pesquisas clínicas em diferentes indicações.


Subject(s)
Humans , Animals , Cannabidiol , Psychiatry , Psychotic Disorders , Botany , Brain Diseases , Cannabinoids , Cannabis , Therapeutic Uses
3.
Rev. Fac. Med. (Bogotá) ; 68(3): 446-452, July-Sept. 2020. tab, graf
Article in English | LILACS, COLNAL | ID: biblio-1143734

ABSTRACT

Abstract Introduction: Medicinal plants have been traditionally used to cure or alleviate infectious and non-infectious diseases. They are widely accepted due to their low cost and low toxicity indexes. These plants are frequently used in cases involving skin irritation, superficial wounds, insect bites, and snake bites. Objective: To compile available evidence on the main therapeutic uses and phytochemical components of Cnidoscolus aconitifolius (popularly known as chaya), a plant that grows in tropical regions of Mexico and Central America. Materials and methods: A literature review of studies on C. aconitifolius published until 2017 was conducted in the BIREME, PubMed/Medline, Elsevier and SciELO databases. Descriptors "Cnidoscolus" and "aconitifolius" were used for the literature search, and no language restrictions were applied. Results: 82 articles were retrieved after completing the initial search. Once the studies were filtered by title (descriptors in the title) and duplicates were removed, 18 articles were reviewed. Based on the information found, it was possible to confirm that this plant has multiple health benefits. Conclusions: The traditional therapeutic use of Cnidoscolus aconitifolius is backed by scientific evidence. Therefore, further research aimed at identifying new phytochemical properties of this plant should be conducted to establish alternative therapies for treating different conditions.


Resumen Introducción. El uso tradicional de plantas medicinales para tratar diferentes enfermedades, ya sean infecciosas o no, es ampliamente aceptado debido a su bajo costo y sus bajos índices de toxicidad. Estas plantas son frecuentemente usadas en casos que involucran irritaciones de la piel, heridas superficiales, picaduras de insectos y mordeduras de víboras. Objetivo. Recopilar la información disponible sobre los principales usos terapéuticos y los componentes fitoquímicos de Cnidoscolus aconitifolius, una planta conocida popularmente como chaya y que crece en regiones tropicales de México y Centroamérica. Materiales y métodos. Se realizó una revisión de la literatura sobre C. aconitifolius publicada hasta 2017 en las bases de datos BIREME, PubMed/Medline, Elsevier y SciELO. Para la búsqueda se emplearon los descriptores "Cnidoscolus" y "aconitifolius", y no se aplicaron filtros de idioma. Resultados. Se identificaron 82 artículos luego de completar la búsqueda inicial. Después de filtrar los estudios por título (presencia de descriptores de búsqueda en el título) y remover duplicados, se incluyeron 18 artículos en la revisión. De acuerdo a la información encontrada, fue posible confirmar que esta planta ofrece diversos beneficios para la salud. Conclusiones. El uso terapéutico tradicional de la chaya está sustentado por evidencia científica, por lo que se sugiere realizar más investigaciones centradas en la identificación de nuevas propiedades fitoquímicas de esta planta y, así, establecer alternativas terapéuticas para distintas afecciones.


Subject(s)
Humans , Plants, Medicinal , Therapeutic Uses , Phytochemicals
4.
Rev. medica electron ; 42(1): 1674-1681, ene.-feb. 2020.
Article in Spanish | LILACS, CUMED | ID: biblio-1127024

ABSTRACT

RESUMEN La terapia transfusional demanda de sólidos conocimientos para lograr planear y ejecutar un plan de trabajo integral para el logro del bienestar de la persona que lo requiera. El personal que desarrolla su profesión en aspectos relacionados con las transfusiones sanguíneas debe estar en una actualización continua de conocimientos, orientados a desarrollar nuevas técnicas así como medidas de seguridad. El objetivo de este trabajo fue abordar acerca de la importancia del uso de la sangre como recurso terapéutico, y el valor hermanado de la donación voluntaria y generoso de sangre lo que vincula al individuo a una nueva conducta y actitud hacia el mundo exterior natural, socia. La sangre constituye la materia prima esencial para los bancos de sangre, de ella se obtiene el plasma, glóbulos rojos, glóbulos blancos, plaquetas, hemoderivados y otros productos biológicos para terapias en la medicina transfusional. La donación voluntaria es una acción desprendida por el solo hecho de ayudar a otros a los que no se conoce, no sólo es la más generosa y la más ética, es el pilar de los servicios modernos de donación y transfusión sanguínea (AU).


SUMMARY Transfusion therapy demands solid knowledge to plan and perform a comprehensive work plan to achieve the wellbeing of persons needing it. The staff whose profession is related with blood transfusions should be continuously updating their knowledge, trying to develop new techniques and secure practices. The aim of this article was approaching the importance of using blood as therapeutic resource and the associated value of generous and voluntary donation, linking individuals to a new behavior and attitude to the natural and social outside world. Blood is the essential raw material for blood banks, obtaining from it plasma, red blood cells, white blood cells, platelets, blood products and other biological products for therapies in transfusion medicine. Voluntary donation is a disinterested action just for the fact of helping unknown persons. It is not only the most generous and the most ethical action, but it is also the support of the modern blood donation and transfusion services (AU).


Subject(s)
Humans , Blood , Blood Donors/ethics , Blood-Derivative Drugs , Blood Banks/methods , Blood Banks/supply & distribution , Blood Platelets , Therapeutic Uses , Transfusion Medicine
5.
Article in Chinese | WPRIM | ID: wpr-827193

ABSTRACT

OBJECTIVE@#To investigate the effect of modified LMB 89± rituximab regimen on long-term clinical benefit for patients with Burkitt lymphoma.@*METHODS@#Clinical data of 43 patients with Burkitt lymphoma were collected and retrospectively analyzed in the period from July 2006 to October 2017. Forty-three patients were divided into 2 groups, including Hyper-CVAD regimen, R-EPOCD regimen or VDCLP regimen treated group as control (20 patients) and modified regimen group with modified LMB 89±rituximab regimen (23 patients); the event-free survival (EFS) rate, overall survival (OS) rate, cumulative incidence of relapse (CIR), non-relapse mortality rate (NRM) and adverse reaction incidence of 2 groups were compared. At the same time, the efficacy analysis for patients of modified regimen group was performed according to age and using rituximab or no.@*RESULTS@#The EFS rate and OS rate of modified regimen group were significantly higher than those of control group (P<0.05). The CRR rate and NRM rate of modified regimen group were significantly lower than those of control group (P<0.05). The EFS rate and OS rate of patients for <40 years old were significantly higher than those of patients for ≥40 years old in modified regimen group (P<0.05). The EFS rate and OS rate of patients with rituximab were significantly higher than those of patients without rituximab in modified regimen group (P<0.05). There was no significant difference in the adverse reaction incidence between 2 groups (P>0.05).@*CONCLUSION@#Modified LMB 89± rituximab regimen in the treatment of patients with Burkitt lymphoma can efficiently prolong survival time and shows the better safety; and the remigen combined with rituximab is more helpful to improve the clinical prognosis and show the better clinical effects for the patients≤40 years old.


Subject(s)
Adult , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Burkitt Lymphoma , Drug Therapy , Cyclophosphamide , Cytarabine , Disease-Free Survival , Doxorubicin , Humans , Methotrexate , Neoplasm Recurrence, Local , Retrospective Studies , Rituximab , Treatment Outcome
6.
Journal of Experimental Hematology ; (6): 1210-1214, 2020.
Article in Chinese | WPRIM | ID: wpr-827138

ABSTRACT

OBJECTIVE@#To analyze the clinical efficacy and safety of rituximab therapy for patients with Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL), and to explore the factors influencing the clinical efficacy.@*METHODS@#According to therapeutic regimen, 66 patients with EBV-positive DLBCL were divided into two groups: CHOP group (32 cases) and R-CHOP group (CHOP+ rituximab, 34 cases). The clinical efficacy and the incidence of complication were compared between two groups. The clinical risk factors for the clinical efficacy in patients with EBV-positive DLBCL were confirmed by multivariate Logistic analysis.@*RESULTS@#Compared with CHOP group, the complete remission rate, partial remission rate and the overall effective rate in R-CHOP group all were high (P<0.05), moreover the disease progression rate in R-CHOP group were low (P<0.05). The occurrences rate of myelotoxicity, hepatic injury and gastrointestinal reaction were not statistically significantly different between two groups (P>0.05). Multivariate Logistic analysis showed that the Ann Arbor staging, IPI risk score and Ki-67 positive rate were independent risk factors for the clinical efficacy in patients with EBV-positive DLBCL (OR=2.689, P=0.038; OR=3.232, P=0.025; OR=2.919, P=0.023).@*CONCLUSION@#The clinical efficacy and safety of the therapy with rituximab on the patients with EBV-positive DLBCL are better. The poor Ann Arbor stage, high IPI risk score and the Ki-67 positive rate are factors affecting the clinical efficacy for the patients with EBV-positive DLBCL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Cyclophosphamide , Therapeutic Uses , Doxorubicin , Therapeutic Uses , Herpesvirus 4, Human , Humans , Lymphoma, Large B-Cell, Diffuse , Drug Therapy , Prednisone , Therapeutic Uses , Rituximab , Therapeutic Uses , Treatment Outcome , Vincristine , Therapeutic Uses
7.
Journal of Experimental Hematology ; (6): 1251-1255, 2020.
Article in Chinese | WPRIM | ID: wpr-827131

ABSTRACT

OBJECTIVE@#To investigate the influence of influence of combination with 1q21 amplification or-no in patients with newly diagnosed MM on the clinical effecacy of bortezomib-based induction chemotherapy and long-term prognosis of patients.@*METHODS@#148 patients with newly diagnosed MM treated from January 2010 to May 2018 were selected and divided into 2 groups: group A (70 patients) without 1q21 amplification and group B (78 patients) with 1q21 amplification; and the survival benefit and influence on clinical efficacy of bortezomib were compared between 2 groups, and the factors influencing clinical prognosis in the patients with newly diagnosed MM were analyzed.@*RESULTS@#The median PFS and OS of patients in B group were significantly shorter than those in group A (P<0.05). There was no significant difference in the median OS and PFS between patients with 1q21 amplification copies number =3 and >3 (P>0.05). Multivariate Cox model analysis indicated that the adverse factors for OS were ISS staging, Hb levels, β2 microglobulin levels and 1q21 amplification respectively, and the adverse factors for PFS were Hb levels and 1q21 amplification respectively in patients with newly diagnosed MM (P<0.05). The very good partial remission rate of newly diagnosed MM patients with 1q21 amplification and bortezomib-based induction chemotherapy were significantly higher than that in the patients without bortezomib-based induction chemotherapy (P<0.05). The median PFS time of newly diagnosed MM patients with 1q21 amplification and auto-HSCT after bortezomib-based induction chemotherapy was significantly longer than that of patients without auto-HSCT (P<0.05).@*CONCLUSION@#1q21 amplification should be the independent risk factor for poor prognosis of patients with newly treated MM. The application of bortezomib-containing induction chemotherapy in patients with 1q21 amplification can efficiently improve the remission rate, while auto-HSCT consolidation therapy may prolong patients' PFS.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Bortezomib , Therapeutic Uses , Disease-Free Survival , Humans , Induction Chemotherapy , Multiple Myeloma , Drug Therapy , Prognosis , Retrospective Studies , Treatment Outcome
8.
Journal of Experimental Hematology ; (6): 1419-1423, 2020.
Article in Chinese | WPRIM | ID: wpr-827101

ABSTRACT

Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2(BCL-2)and has great potential in treating a variety of hematological tumors. In recent years, domestic and foreign scholars have tried to use venetoclax singal or in combination with some drugs to treat the patients with hematological tumors, including elderly acute myeloid leukemia(AML)patients un suitable for intensive chemotherapy, relapsed or refractory chronic lymphocytic leukemia(CLL), Non-Hodgkin's lymphoma(NHL)and multiple myeloma(MM)patients, these studies have achieved good results.At the same time,some scholars found that the secondary drug-resistance occurred in some patients who continuous treated with Venetoclax, and explored the Venetoclax-resistant mechanism. In this review, the research advance of Venetoclax in hematological tumors and the mechanisms of drug resistance are summarized and discussed briefly.


Subject(s)
Aged , Antineoplastic Agents , Therapeutic Uses , Bridged Bicyclo Compounds, Heterocyclic , Therapeutic Uses , Hematologic Neoplasms , Humans , Leukemia, Lymphocytic, Chronic, B-Cell , Drug Therapy , Sulfonamides
9.
Protein & Cell ; (12): 707-722, 2020.
Article in English | WPRIM | ID: wpr-827023

ABSTRACT

The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS.


Subject(s)
Adoptive Transfer , Alveolar Epithelial Cells , Pathology , Animals , Apoptosis , Betacoronavirus , Body Fluids , Metabolism , CD4-Positive T-Lymphocytes , Allergy and Immunology , Clinical Trials as Topic , Coinfection , Therapeutics , Coronavirus Infections , Allergy and Immunology , Disease Models, Animal , Endothelial Cells , Pathology , Extracorporeal Membrane Oxygenation , Genetic Therapy , Methods , Genetic Vectors , Therapeutic Uses , Humans , Immunity, Innate , Inflammation Mediators , Metabolism , Lung , Pathology , Mesenchymal Stem Cell Transplantation , Methods , Mesenchymal Stem Cells , Physiology , Multiple Organ Failure , Pandemics , Pneumonia, Viral , Allergy and Immunology , Respiratory Distress Syndrome , Allergy and Immunology , Pathology , Therapeutics , Translational Medical Research
10.
Protein & Cell ; (12): 723-739, 2020.
Article in English | WPRIM | ID: wpr-827018

ABSTRACT

Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. Herein, we identified two potent inhibitors of human DHODH, S312 and S416, with favorable drug-likeness and pharmacokinetic profiles, which all showed broad-spectrum antiviral effects against various RNA viruses, including influenza A virus, Zika virus, Ebola virus, and particularly against SARS-CoV-2. Notably, S416 is reported to be the most potent inhibitor so far with an EC of 17 nmol/L and an SI value of 10,505.88 in infected cells. Our results are the first to validate that DHODH is an attractive host target through high antiviral efficacy in vivo and low virus replication in DHODH knock-out cells. This work demonstrates that both S312/S416 and old drugs (Leflunomide/Teriflunomide) with dual actions of antiviral and immuno-regulation may have clinical potentials to cure SARS-CoV-2 or other RNA viruses circulating worldwide, no matter such viruses are mutated or not.


Subject(s)
Animals , Antiviral Agents , Pharmacology , Therapeutic Uses , Betacoronavirus , Physiology , Binding Sites , Cell Line , Coronavirus Infections , Drug Therapy , Virology , Crotonates , Pharmacology , Cytokine Release Syndrome , Drug Therapy , Drug Evaluation, Preclinical , Gene Knockout Techniques , Humans , Influenza A virus , Leflunomide , Pharmacology , Mice , Mice, Inbred BALB C , Orthomyxoviridae Infections , Drug Therapy , Oseltamivir , Therapeutic Uses , Oxidoreductases , Metabolism , Pandemics , Pneumonia, Viral , Drug Therapy , Virology , Protein Binding , Pyrimidines , RNA Viruses , Physiology , Structure-Activity Relationship , Toluidines , Pharmacology , Ubiquinone , Metabolism , Virus Replication
11.
Chinese Journal of Biotechnology ; (12): 571-592, 2020.
Article in Chinese | WPRIM | ID: wpr-827010

ABSTRACT

The ongoing outbreak of the coronavirus disease 2019 (COVID-19) as named by the World Health Organization has millions of confirmed cases around the world and has claimed hundreds of thousands of lives. The virus was named SARS-CoV-2 in February by International Committee on Taxonomy of Viruses. COVID-19 presents as fever, dry cough, dyspnea, headache and pneumonia. In a small subset of severe cases, the disease quickly progresses to respiratory failure and even death. Since the 21st century, there have been three major outbreaks caused by human coronaviruses, including the severe acute respiratory syndrome (SARS) that broke out in 2003, the Middle East respiratory syndrome (MERS) in 2012, and the recent pandemic of COVID-19. Since 2003, significant progress has been made in the study of SARS-CoV and MERS-CoV concerning their natural origins, pathogenesis, antiviral development and vaccine design. Since SARS-CoV-2 and SARS-CoV are closely related, previous findings on SARS-CoV are highly relevant to a better understanding as well as diagnosis, treatment, prevention and control of SARS-CoV-2. In this review, we highlight recent progresses in the field; compare the biological characteristics of SARS-CoV and SARS-CoV-2; summarize the urgently-needed diagnostic, treatment, prevention and control options; and provide future perspectives for the outcome of the outbreak and research questions to be answered, including some of the difficulties in vaccine development. Hopefully, our comments and suggestions would prove useful for the control of the SARS-CoV-2 epidemic in China and the world.


Subject(s)
Antiviral Agents , Pharmacology , Therapeutic Uses , Betacoronavirus , Allergy and Immunology , Virulence , Coronavirus Infections , Diagnosis , Therapeutics , Virology , Humans , Middle East Respiratory Syndrome Coronavirus , Allergy and Immunology , Virulence , Pandemics , Pneumonia, Viral , Diagnosis , Therapeutics , Virology , SARS Virus , Allergy and Immunology , Virulence , Severe Acute Respiratory Syndrome , Diagnosis , Therapeutics , Virology , Viral Vaccines
12.
Chinese Journal of Biotechnology ; (12): 605-611, 2020.
Article in Chinese | WPRIM | ID: wpr-827008

ABSTRACT

Cyclophilin A (CypA) is a widely distributed and highly conserved protein in organisms. It has peptidyl-prolyl cis/trans isomerase activity and is a receptor for cyclosporin A (CsA). Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses. Seven types of coronaviruses are currently known to infect humans, among which SARS-CoV, MERS-CoV, and SARS-CoV-2 are fatal for humans. It is well established that CypA is essential for the replication of various coronaviruses such as SARS-CoV, CoV-229E, CoV-NL63, and FCoV. Additionally, CsA and its derivatives (ALV, NIM811, etc.) have obvious inhibitory effects on a variety of coronaviruses. These results suggest that CypA is a potential antiviral target and the existing drug CsA might be used as an anti-coronavirus drug. At the end of 2019, SARS-CoV-2 raged in China, which seriously theatern human health and causes huge economic lases. In view of this, we describe the effects of CypA on the replication of coronaviruses and the antiviral activities of its inhibitors, which will provide the scientific basis and ideas for the development of antiviral drugs for SARS-CoV-2.


Subject(s)
Antiviral Agents , Pharmacology , Therapeutic Uses , Betacoronavirus , Coronavirus , Coronavirus Infections , Drug Therapy , Epidemiology , Virology , Cyclophilin A , Cyclosporine , Chemistry , Pharmacology , Therapeutic Uses , Humans , Pandemics , Pneumonia, Viral , Drug Therapy , Epidemiology , Virology , SARS Virus , Virus Replication
13.
Chinese Journal of Lung Cancer ; (12): 247-254, 2020.
Article in Chinese | WPRIM | ID: wpr-826985

ABSTRACT

BACKGROUND@#With the rapid spread of novel coronavirus pneumonia (NCP) worldwide and the escalation of prevention and control efforts, the routine medical needs of patients have been restricted. The aims were to investigate medical needs of lung cancer patients and their mental health status during the epidemic periods, so as to provide rational recommendations for subsequent diagnosis and treatment.@*METHODS@#The questionnaire was sent in the form of an electronic questionnaire at 7am on 4th, March, 2020, until 7am 6th, March, 2020, 368 questionnaires were recollected from 25 provinces (autonomous regions/municipalities) in 48 h.@*RESULTS@#Of the 368 patients, 18 patients were excluded as they didn't receive anti-tumor treatment, and 350 patients were included in the final analysis. 229 cases were treated with oral targeted drugs, and 121 cases were treated with chemotherapy or immunotherapy. 41.3% of patients treated with intravenous chemotherapy or immunotherapy experienced treatment discontinuation, and the proportion of treatment discontinuation in chemotherapy or immunotherapy was higher than those treated with oral targeted drugs (21.0%). Whether oral targeted drugs or intravenous chemotherapy or immunotherapy, more than 60% of patients experienced delays in imaging examinations. Nearly one third of patients developed new symptoms or exacerbation of existing symptoms. 26.6%-28.9% of patients have changed their treatment plans through online consultation. During novel coronavirus pneumonia, 40%-75% of lung cancer patients have mental health problems, and more than 95% of patients support government's prevention and control measures.@*CONCLUSIONS@#During the emergence of NCP, the medical needs of patients with lung cancer have not been enough, especially those who discontinued chemotherapy or immunotherapy. When medical institution resumes work, priority should be given to them. At the same time, mental health problems of patients should be valued and resolved timely.


Subject(s)
Adult , Aged , Antineoplastic Agents , Therapeutic Uses , Betacoronavirus , Physiology , China , Epidemiology , Coronavirus Infections , Epidemiology , Virology , Female , Humans , Lung Neoplasms , Drug Therapy , Psychology , Male , Middle Aged , Pandemics , Pneumonia , Epidemiology , Virology , Pneumonia, Viral , Epidemiology , Virology , Retrospective Studies
14.
Article in English | WPRIM | ID: wpr-811189

ABSTRACT

Chronic Kidney disease (CKD) disturbs mineral homeostasis leading to mineral and bone disorders (MBD). Serum calcium and phosphate (Pi) remain normal until the late stages of CKD at the expense of elevate fibroblast growth factor-23 (FGF-23), a phosphaturic hormone, followed by reduced 1,25-dihydroxy-vitamin D (1,25[OH]2D) and finally elevated parathyroid hormone (PTH). Pi retention is thought to be the initial cause of CKD-MBD. The management of MBD is a huge clinical challenge because the effectiveness of current therapeutic regimens to prevent and treat MBD is limited. An intermittent regimen of PTH, when administered at the early stages of CKD, through its phosphaturic action, could prevent FGF-23 increases, the drop of 1,25(OH)2D, and the development of renal osteodystrophy, including secondary hyperparathyroidism (HPT) and its catabolic effects on the skeleton. Even in more advanced stages of CKD that have not progressed to tertiary HPT, could be beneficial. Therapeutic effects could be achieved in vascular calcification as well. Limited experimental/clinical data support the effectiveness of PTH in CKD-MBD. Its safety, has been established only when it is used for the treatment of osteoporosis, including patients with CKD. The proposed intermittent PTH administration is biologically plausible but its effectiveness and safety has to be critically assessed in long term prospective studies in patients with CKD-MBD.


Subject(s)
Calcium , Fibroblasts , Homeostasis , Humans , Hyperparathyroidism, Secondary , Miners , Osteoporosis , Parathyroid Hormone , Prospective Studies , Renal Insufficiency, Chronic , Chronic Kidney Disease-Mineral and Bone Disorder , Skeleton , Therapeutic Uses , Vascular Calcification
15.
Article in Chinese | WPRIM | ID: wpr-826729

ABSTRACT

OBJECTIVE@#To evaluate the clinical efficacy of medicinal penetration on acupoint combined with medication for histiocytic necrotizing lymphadenitis (HNL) of heat-toxin syndrome, and to explore the methods of improving the clinical effect.@*METHODS@#A total of 72 cases with HNL with heat-toxin syndrome were randomly divided into an observation group and a control group, 36 cases in each group. The patients in the control group were treated with oral administration of prednisone tablets for 40 days (first 5 days: 10 mg, three times a day; since then, reduced by 5 mg every 7 days). In the observation group, on the basis of the medication in the control group, the patients were treated with acupoint application and ultrasonic drug penetration therapy, once a day for 14 days. The acupoints of Waiguan (TE 5), Fengchi (GB 20) of affected side and points were selected. The changes of target lymph node swelling, visual analogue score (VAS), axillary temperature and total score of symptoms and signs were evaluated before treatment and 7, 14, 28 and 40 d into treatment; the changes of white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and lactic dehydrogenase (LDH) were evaluated on 14 d and 40 d into treatment; the patients were followed-up for half a year.@*RESULTS@#① Fourteen days into treatment, the clinical cured rate in the observation group was 38.9% (14/36), which was superior to 16.7% (6/36) in the control group (0.05). ④ The recurrence rate in the observation group was 5.6% (2/36), which was similar to 16.7% (6/36) in the control group (>0.05).@*CONCLUSION@#The medicinal penetration on acupoint as adjunctive treatment could effectively relieve the discomfort symptoms of HNL patients with syndrome of heat and toxin, improve the clinical cured rate, and provide the research direction for shortening the course of medication.


Subject(s)
Acupuncture Points , Acupuncture Therapy , Histiocytic Necrotizing Lymphadenitis , Therapeutics , Humans , Medicine, Chinese Traditional , Prednisone , Therapeutic Uses , Treatment Outcome
16.
Article in Chinese | WPRIM | ID: wpr-826727

ABSTRACT

OBJECTIVE@#To compare the therapeutic effect of electroacupuncture (EA) combined with donepezil hydrochloride and donepezil hydrochloride alone on improving learning-memory ability in patients with Alzheimer's disease (AD), and to explore its action mechanism.@*METHODS@#Sixty patients of AD were randomly divided into an observation group and a control group, 30 cases in each group. The patients in the observation group were treated with EA at governor vessel (GV) combined with donepezil hydrochloride. EA was applied at Baihui (GV 20) and Fengfu (GV 16) with dilatational wave (10 Hz/50 Hz of frequency, 0.5 to 5.0 mA of intensity), and the needles were kept for 40 min, EA was given once a day; the donepezil hydrochloride tablet was taken orally, 5 mg, once a day, and after 4 weeks the dosage might be increased to 10 mg per day according to the specific situation. All the treatment was given for 8 weeks. The patients in the control group were only treated with donepezil hydrochloride with the identical procedure as the observation group. The Montreal cognitive assessment (MoCA) and Alzheimer's disease assessment scale cognitive part (ADAS-Cog) were evaluated before and after treatment; P300 (latency and amplitude of N2 and P3) was detected by EEG/ERP system brain event related potential instrument, and amyloid precursor protein (APP) and β-amyloid protein 1-42 (Aβ) were detected by ELISA.@*RESULTS@#Compared before treatment, the MoCA scores were increased after treatment in the two groups (<0.05), and the MoCA score in the observation group was higher than that in the control group (<0.05). Compared before treatment, the ADAS-Cog scores were decreased after treatment in the two groups (<0.05), and the ADAS-Cog score in the observation group was lower than that in the control group (<0.05). Compared before treatment, the latency of N2 and P3 was shortened and the amplitude was increased after treatment in the two groups (<0.05); after treatment, the latency of N2 and P3 in the observation group was shorter than that in the control group and the amplitude was higher than that in the control group (<0.05). Compared before treatment, the serum levels of APP and Aβ were lower after treatment in the two groups (<0.05), and the serum levels of APP and Aβ in the observation group were lower than those in the control group (<0.05).@*CONCLUSION@#EA at Baihui (GV 20) and Fengfu (GV 6) combined with donepezil hydrochloride can effectively reduce the serum levels of APP and Aβ and improve the scores of MoCA and ADAS-Cog and the levels of N2 and P3 of P300 in AD patients, which has superior effect to donepezil hydrochloride alone in improving the learning-memory of AD patients.


Subject(s)
Alzheimer Disease , Blood , Therapeutics , Amyloid beta-Peptides , Blood , Amyloid beta-Protein Precursor , Blood , Cognition , Donepezil , Therapeutic Uses , Electroacupuncture , Humans , Learning , Memory , Peptide Fragments , Blood
17.
Article in Chinese | WPRIM | ID: wpr-826723

ABSTRACT

OBJECTIVE@#To observe the direct intervention effects of electroacupuncture (EA) and non-steroid anti-inflammatory drugs (NSAIDs) on pain memory, and to explore their effects on cAMP/PKA/cAMP pathway in anterior cingulate gyrus (ACC).@*METHODS@#Fifty clean healthy male SD rats were randomly divided into a control group, a model group, an indomethacin group, an EA group and a sham EA group, 10 rats in each group. Except the control group, the pain memory model was established in the remaining four groups by twice injection of carrageenan at foot; 0.1 mL of 2%λ-carrageenan was subcutaneously injected at the left foot of rats; 14 days later, when the pain threshold of rats of each group returned to the basic level, the second injection was performed with the same procedure. The rats in the EA group were treated with EA at bilateral "Zusanli" (ST 36) for 30 min; the rats in the indomethacin group was treated with indomethacin intragastric administration with the dose of 3 mg/kg; the rats in the sham EA group was treated with EA without electricity at the point 0.3 mm forward "Zusanli" (ST 36) with the depth of 2 mm for 30 min; the rats in the control group was not given any invention. All the above interventions were performed 5 h, 1 d, 2 d and 3 d after the second injection of 2% λ-carrageenan. The left-side paw withdrawal thresholds (PWT) were observed before the first injection, 4 h, 3 d, 5 d after the first injection, before the second injection and 4 h, 1 d, 2 d, 3 d after the second injection. Three days after the second injection, the number of positive cells of cAMP, p-PKA, p-CREB and the number of positive cells of protein co-expression in the right ACC brain area were detected by immunofluorescence, and the relative protein expression of p-PKA and p-CREB were detected by Western blot.@*RESULTS@#Compared with the control group, the PWTs in the model group decreased significantly 4 h, 3 d and 5 d after the first injection and 1 d, 2 d and 3 d after the second injection (<0.05); compared with the control group, the positive expression of cAMP, p-PKA and p-CREB in the right ACC brain area in the model group increased significantly (<0.05), and the number of positive cells of the co-expression of cAMP/p-PKA and p-PKA/p-CREB also increased significantly (<0.05). Compared with the model group, indomethacin group and sham EA group, the PWTs in the EA group were increased significantly 1 d, 2 d and 3 d after the second injection (<0.05); compared with the model group, indomethacin group and sham EA group, the positive expression of p-PKA and p-CREB in the right ACC brain area in the EA group decreased significantly (<0.05), and the number of positive cells of co-expression of cAMP/p-PKA and p-PKA/p-CREB was decreased significantly (<0.05). Compared with the model group and sham EA group, the positive expression of cAMP in the right ACC brain area was decreased in the EA group (<0.05).@*CONCLUSION@#EA have a direct intervention effect on pain memory, which have significant advantage over NSAIDs in the treatment of chronic pain. The advantage effect of EA on pain memory may be related to the inhibition of cAMP/PKA/CREB pathway in ACC area.


Subject(s)
Animals , Anti-Inflammatory Agents, Non-Steroidal , Therapeutic Uses , Cyclic AMP , Metabolism , Cyclic AMP Response Element-Binding Protein , Metabolism , Cyclic AMP-Dependent Protein Kinases , Metabolism , Electroacupuncture , Gyrus Cinguli , Metabolism , Male , Pain Threshold , Random Allocation , Rats , Rats, Sprague-Dawley , Signal Transduction
18.
Article in Chinese | WPRIM | ID: wpr-826707

ABSTRACT

OBJECTIVE@#To compare the clinical effect on gastroesophageal reflux asthma between the needling technique of acupuncture (acupuncture for promoting the circulation of the governor vessel and reducing the reversed ) and omeprazole enteric capsules (OME).@*METHODS@#A total of 60 patients with gastroesophageal reflux asthma were randomized into an acupuncture group and a western medication group, 30 cases in each one. The basic treatment for anti-bronchial asthma was provided in both of the groups. Additionally, OME was prescribed for oral administration in the western medication group, twice a day, 20 mg each time, for 8 weeks. In the acupuncture group, the needling technique of acupuncture was added. The needles were inserted at the sites inferior to the spinous processes of T to T. Acupuncture was given once in the morning on Tuesday, Thursday and Saturday respectively, totally for 8 weeks. Separately, before and after treatment, the score of reflux disease diagnostic questionnaire (RDQ), the score of asthma control test (ACT) and the tenderness threshold at the sites inferior to the spinous processes of T to T were observed and the clinical effect was evaluated in the two groups.@*RESULTS@#①The remarkably effective and curative rate was 46.7% (14/30) in the acupuncture group, higher than 3.3% (1/30) in the western medication group (<0.01). The asthma control rate was 66.7% (20/30) in the acupuncture group, higher than 13.3% (4/30) in the western medication group (<0.01). ②RDQ score after treatment was lower than that before treatment in either group (<0.05). The decrease range of RDQ score in the acupuncture group was larger than that of the western medication group (<0.05). After treatment, ACT score was increased as compared with that before treatment in either group (<0.05) and the increase range of ACT score in the acupuncture group was larger than that of the western medication group (<0.05). ③The tenderness thresholds at the sites inferior to the spinous processes of T to T and T to T were all increased after treatment as compared with those before treatment in the acupuncture group separately (<0.05). In the western medication group, the thresholds were only increased at the sites inferior to the spinous processes of T, T and T after treatment as compared with those before treatment separately (<0.05). After treatment, the tenderness thresholds at T to T in the acupuncture group were all higher than the western medication group (<0.05).@*CONCLUSION@#The needling technique of acupuncture effectively relieves the symptoms of gastroesophageal reflux asthma and improves the quality of life in the patients and its effect is better than omeprazole enteric capsules.


Subject(s)
Acupuncture Points , Acupuncture Therapy , Asthma , Therapeutics , Gastroesophageal Reflux , Therapeutics , Humans , Omeprazole , Therapeutic Uses , Quality of Life , Treatment Outcome
19.
Article in Chinese | WPRIM | ID: wpr-826700

ABSTRACT

Professor believes that infantile cerebral palsy is located in the brain and closely related to the kidney. The clinical treatment should focus on the brain theory and root at the kidney. In pathogenesis, infantile spastic cerebral palsy refers to flaccidity of and spasticity of . The principle of treatment should be balancing and , promoting the circulation of the governor vessel and regulating the spirit/mind. In clinical treatment, the comprehensive therapy of acupuncture and herbal medicine is adopted. In acupuncture, the acupoints on the head and the face are dominant and the body acupoints are selected rigorously and precisely. The herbal formula with and is used and taken orally with warm water. In acupoint application treatment, and are the main herbal medicines for the external application at Shenque (CV 8) and Baihui (GV 20). All of the above therapies are used in combination to co-achieve the effect of regaining consciousness, opening orifices and benefiting the intelligence. The clinical therapeutic effect of this comprehensive therapy is significant.


Subject(s)
Acupuncture Points , Acupuncture Therapy , Cerebral Palsy , Therapeutics , Herbal Medicine , Humans , Plant Preparations , Therapeutic Uses
20.
Article in Chinese | WPRIM | ID: wpr-826688

ABSTRACT

OBJECTIVE@#To observe the prevention effect of transcutaneous electrical acupoint stimulation (TEAS) for chemotherapy-related myelosuppression in non-small cell lung cancer.@*METHODS@#A total of 102 patients with non-small cell lung cancer who received initial chemotherapy were randomly divided into a conventional group, a medication group and a TEAS group, 34 cases in each one. The conventional group was treated with chemotherapy of gemcitabine combined with cisplatin and given routine care. On the basis of conventional group's treatment, the medication group was given tablets before chemotherapy, 2-3 tablets each time, 3 times a day. In the TEAS group, on the basis of conventional group's treatment, TEAS was applied at Dazhui (GV 14), Geshu (BL 17), Hegu (LI 4), Zusanli (ST 36) and Sanyinjiao (SP 6) on day 1, 2, 3, 5, 8, 14, 21 and 28 of chemotherapy. The treatment was given 30 min each time and once a day. In the three groups, the treatment for 28 days was as one course and one course of treatment was required. The changes of leukocytes, platelets, erythrocyte, hemoglobin indexes in patients of the three groups were observed one day before chemotherapy and on day 5, 8, 11, 14, 21 and 28 of chemotherapy. The comfort situation of patients was observed one day before chemotherapy and on the 5th, 11th and 21st day of chemotherapy.@*RESULTS@#Compared with before chemotherapy, the leukocyte counts of three groups were decreased at various time points after chemotherapy (<0.05). Compared with the conventional group, the leukocyte counts were higher on day 8 and 14 in the TEAS group and on day 14 in the medication group (<0.05). Compared with before chemotherapy, the platelet count decreased on the day 5, 8, 11 and 14 of chemotherapy in the conventional group (<0.05), and the platelet counts all decreased at each time point after chemotherapy in the medication group (<0.05). The platelet counts of the TEAS group on day 5, 8, 11 and 14 of chemotherapy were higher than those of the conventional group (<0.05), and the platelet counts of the TEAS group on day 5, 8, 11 and 21 of chemotherapy were higher than those of the medication group (<0.05). Compared with the conventional group, the comfort situation scores of the TEAS group were higher on the 5th and 11th days of chemotherapy (<0.05).@*CONCLUSION@#Transcutaneous electrical acupoint stimulation can prevent chemotherapy-induced myelosuppression (leukocyte, platelets) in patients with non-small cell lung cancer and improve patient comfort situation.


Subject(s)
Acupuncture Points , Bone Marrow , Carcinoma, Non-Small-Cell Lung , Drug Therapy , Therapeutics , Cisplatin , Therapeutic Uses , Deoxycytidine , Therapeutic Uses , Drugs, Chinese Herbal , Therapeutic Uses , Humans , Lung Neoplasms , Drug Therapy , Therapeutics , Transcutaneous Electric Nerve Stimulation
SELECTION OF CITATIONS
SEARCH DETAIL